Join
Live feed
·
PRReleasevia Quantisnow
Soligenix Inc. logo

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

ByQuantisnow·Wall Street's wire, on your screen.
SNGX· Soligenix Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SNGX (Soligenix Inc.) and more on Quantisnow.